Trial Profile
Assessment of micro-bleeding after prophylaxis with enoxaparin or rivaroxaban against venous thromboembolic disease following hip and knee arthroplasty.
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Acronyms PREVENT
- 21 Apr 2016 Status changed from recruiting to completed.
- 10 Sep 2009 New trial record